• Home
  •  / Ra Pharmaceuticals

Ra Pharmaceuticals

OverviewSuggest Edit

Ra Pharma® is a clinical-stage biopharmaceutical company using a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system.
TypePublic
Founded2008
HQCambridge, MA, USMap
Websiterapharma.com
Overall CultureCMore
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)89(+24%)
Revenue (FY, 2019)$3 M(+20%)
Share Price (Apr 2020)$48
Cybersecurity ratingAMore

Key People/Management at Ra Pharmaceuticals

Edward Mathers

Edward Mathers

Chairman
Peter Diroma

Peter Diroma

Senior Vice President, Regulatory, Quality, and Government Affairs
Joe Shulman

Joe Shulman

Senior Vice President, Technical Operations
Doug Treco

Doug Treco

President and CEO
Show more

Ra Pharmaceuticals Office Locations

Ra Pharmaceuticals has an office in Cambridge
Cambridge, MA, US (HQ)
87 Cambridgepark Dr
Show all (1)

Ra Pharmaceuticals Financials and Metrics

Ra Pharmaceuticals Revenue

Ra Pharmaceuticals's revenue was reported to be $3 m in FY, 2019
USD

Revenue (FY, 2019)

3.0m

Net income (FY, 2019)

(102.7m)

EBIT (FY, 2019)

(107.0m)

Market capitalization (9-Apr-2020)

2.3b

Closing stock price (9-Apr-2020)

48.0

Cash (31-Dec-2019)

265.0m

EV

2.0b
Ra Pharmaceuticals's current market capitalization is $2.3 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.9m2.5m3.0m

General and administrative expense

5.0m9.8m14.4m27.3m

R&D expense

27.9m45.3m54.4m82.6m

Operating expense total

33.0m55.0m68.9m110.0m
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

3.0m

General and administrative expense

1.0m2.5m2.3m2.3m3.3m3.8m3.5m4.8m4.9m

R&D expense

7.1m9.0m10.5m13.1m13.4m12.3m13.4m15.3m17.9m

Operating expense total

8.1m11.5m12.8m15.4m16.7m16.1m16.9m20.1m22.8m
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

117.8m70.4m209.8m265.0m

Prepaid Expenses

2.5m2.6m9.7m

Inventories

1.7m

Current Assets

119.5m72.9m212.4m274.7m
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

31.2m105.4m96.6m84.1m109.1m95.1m81.1m191.6m173.6m292.6m

Prepaid Expenses

669.0k1.6m1.2m1.1m1.7m3.1m2.5m3.9m6.1m7.6m

Current Assets

31.9m107.0m97.8m85.2m110.9m98.1m83.6m195.6m179.7m300.2m

PP&E

5.7m6.2m6.2m6.0m5.6m5.7m5.4m5.0m4.8m4.5m
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(28.9m)(54.4m)(64.9m)(102.7m)

Depreciation and Amortization

1.3m1.5m1.6m1.6m

Inventories

(890.0k)

Accounts Payable

4.0m2.0m1.1m7.0m
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(18.0m)(11.4m)(24.0m)(39.3m)(16.5m)(32.2m)(48.7m)(19.0m)(40.9m)(65.9m)

Depreciation and Amortization

1.0m346.0k730.0k1.1m386.0k772.0k1.2m530.0k1.1m1.6m

Accounts Payable

2.9m(2.0m)(96.0k)963.0k(2.1m)(693.0k)(757.0k)(887.0k)1.1m1.2m

Cash From Operating Activities

(12.8m)(12.0m)(20.9m)(33.1m)(15.5m)(29.0m)(42.9m)(18.0m)(36.4m)(58.7m)
show all
USDQ3, 2016

Financial Leverage

-0.7 x
Show all financial metrics

Ra Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

Learn more about our premium products
SecurityScorecard logo

Ra Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Ra Pharmaceuticals Online and Social Media Presence

Ra Pharmaceuticals's Trends

Embed Graph

Ra Pharmaceuticals Company Culture

  • Overall Culture

    C

    71/100

  • CEO Rating

    A+

    86/100

  • Compensation

    D+

    61/100

  • Diversity

    D+

    70/100

Learn more on Comparably

Ra Pharmaceuticals News and Updates

October 10, 2019

Belgium's UCB to buy Ra Pharmaceuticals for $2.1 bln

UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.
July 23, 2018

Riding Ra Pharmaceuticals

Ra Pharmaceuticals Blogs

February 28, 2020

Ra Pharmaceuticals Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13 th Annual Rare Disease Day ® , an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the
February 27, 2020

Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Enrollment ongoing in Phase 3 clinical trial of zilucoplan in gMG, with top-line results expected in early 2021 First patient dosed in Phase 2 clinical trial of zilucoplan in IMNM, with top-line results expected in the second half of 2020 IND cleared by FDA for the HEALEY ALS Platform Trial at Mass
February 18, 2020

Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology

Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology Content Import Tue, 02/18/2020 - 07:00 Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology February 18, 2020 at 7:00 AM EST …
January 22, 2020

Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial

Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial Content Import Wed, 01/22/2020 - 09:01 Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial January 22, 2020 at 9:00 AM EST This …
December 04, 2019

Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM

Top-line results expected in the second half of 2020 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 4, 2019-- Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in its Phase 2 clinical trial of zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM).
November 07, 2019

Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

First patient dosed in the global, pivotal, Phase 3 RAISE study of zilucoplan in gMG, with top-line results expected in early 2021 On track to dose first patient in the Phase 2 trial of zilucoplan in immune-mediated necrotizing myopathy (IMNM) by year-end 2019 Zilucoplan selected by leading experts
Show more

 Ra Pharmaceuticals Frequently Asked Questions

  • When was Ra Pharmaceuticals founded?

    Ra Pharmaceuticals was founded in 2008.

  • Who are Ra Pharmaceuticals key executives?

    Ra Pharmaceuticals's key executives are Edward Mathers, Peter Diroma and Joe Shulman.

  • How many employees does Ra Pharmaceuticals have?

    Ra Pharmaceuticals has 89 employees.

  • What is Ra Pharmaceuticals revenue?

    Latest Ra Pharmaceuticals annual revenue is $3 m.

  • What is Ra Pharmaceuticals revenue per employee?

    Latest Ra Pharmaceuticals revenue per employee is $33.7 k.

  • Who are Ra Pharmaceuticals competitors?

    Competitors of Ra Pharmaceuticals include Unither Pharmaceuticals, Merz North America and Aurobindo Pharma.

  • Where is Ra Pharmaceuticals headquarters?

    Ra Pharmaceuticals headquarters is located at 87 Cambridgepark Dr, Cambridge.

  • Where are Ra Pharmaceuticals offices?

    Ra Pharmaceuticals has an office in Cambridge.

  • How many offices does Ra Pharmaceuticals have?

    Ra Pharmaceuticals has 1 office.